Farwell Wildon 4
4 · Dyne Therapeutics, Inc. · Filed Feb 14, 2024
Insider Transaction Report
Form 4
Farwell Wildon
Chief Medical Officer
Transactions
- Sale
Common Stock
2024-02-12$25.07/sh−5,493$137,710→ 163,503 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 14, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F3]Includes 145,667 unvested RSUs.